Archived Newsletters

  1. 03.25.26 -- The Jones Act Hurts U.S. Pharmaceutical Manufacturing 3/25/2026
    03/25/26 Outsourced Pharma Newsletter
  2. 03.24.26 -- Is Your Sterile Injectable Strategy Built For Scale? 3/24/2026

    03/24/26 Outsourced Pharma Newsletter

  3. 03.24.26 -- The Long Road To U.S. Vaccine Manufacturing 3/24/2026
    03/24/26 Outsourced Pharma Newsletter
  4. 03.23.26 -- STREAM Edition: A New STREAM Of Innovations: Safe Nucleic Acid Delivery & Next‑Gen Biopharma 3/23/2026

    03/23/26 Outsourced Pharma Newsletter

  5. 03.23.26 -- Six Specialized Modalities Testing CDMO Readiness In 2026 3/23/2026
    03/23/26 Outsourced Pharma Newsletter
  6. 03.21.26 -- Advising The Biotech C-Suite To Reconsider Quality 3/21/2026
    03/21/26
  7. 03.20.26 -- A Woman Relegated To The Manufacturing Night Shift 3/20/2026
    03/20/26 Outsourced Pharma Newsletter
  8. 03.19.26 -- Your Guide To AAV Success: Characterization, QC, And Viral Clearance Strategies 3/19/2026

    03/19/26 Outsourced Pharma Newsletter

  9. 03.19.26 -- The Long Road To U.S. Vaccine Manufacturing 3/19/2026
    03/19/26 Outsourced Pharma Newsletter
  10. 03.18.26 -- Struggling with mAb aggregation and other impurities? 3/18/2026

    03/18/26 Outsourced Pharma Newsletter